Renibus Therapeutics has dosed the first subject in the Phase III PROTECT clinical trial of RBT-1 (stannic protoporfin/iron sucrose), a preconditioning agent, in individuals who undergo cardiothoracic surgery.
The double-blind, randomised, placebo-controlled trial is designed to assess the effect of RBT-1 in cutting down the risk of postoperative complications following cardiac surgery.
It will enrol nearly 400 participants at around 35 sites in the US and Canada.
A composite hierarchy based on severity utilising the Win-Ratio or Finkelstein-Schoenfeld method is the trial’s primary endpoint.
Time on the ventilator, blood product requirements, development of atrial fibrillation, delirium, hospital stay duration, cost-effective analyses and safety are the trial’s secondary and exploratory objectives.
Top-line data from the PROTECT study are anticipated in mid-2025 with the submission of a new drug application (NDA) slated for 2026.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
A fixed-dose combination product, RBT-1 should be administered intravenously for one to two hours, 24 to 48 hours before the surgical procedure.
In a completed Phase II trial, the agent showed positive data in primary and several secondary endpoints, offering shorter ICU time, patient recovery time and fewer hospital readmissions.
Renibus co-CEO Frank Stonebanks said: “With our pivotal trial now underway in our PROTECT programme, we are considering ways to expand the opportunity with RBT-1 across a wide spectrum of procedures and post-operative complications, including potentially transplant surgeries, TAVR’s (trans aortic valve replacements) and thoracic aortic aneurysms.
“We believe that RBT-1 has broad ‘pipeline-in-a-product’ potential, and we look forward to executing well in Phase III and bringing our product to patients in need.”